GENFIT

AGM Information • Apr 3, 2014

www.genfit.com

Press Release Communiqué de Presse 2014

GENFIT: MINUTES OF THE COMBINED SHAREHOLDERS' MEETING OF APRIL 2, 2014

The large majority of shareholders adopted the totality of resolutions proposed by the Management Board

Lille (France), Boston (Massachusetts, United States), April 3 rd, 2014 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that its share holders have voted in favor of the totality of the resolutions proposed by the Management Board during the Combined Shareholders' Meeting that was held in Lille on April 3, 2014.

The shareholders approved all the resolutions proposed by the Management Board by a large majority of at least 94% of the cast votes.

Jean-François Mouney, Chairman and CEO of GENFIT, declared: "I am very pleased with the very strong adhesion of the many stock holders, both institutional and individual, to the propositions made by the General Management of the Company to obtain the means for its development. This satisfaction is within an international context where GENFIT remains an attractive value for investors, especially in light of the stock price of its principal competitors in NASH."

The detail of the voting results is available on www.genfit.com.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts: GENFIT Jean-François Mouney – CEO & Chairman of the Management Board Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr